Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APLS NASDAQ:INSM NASDAQ:LEGN NASDAQ:NKTR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLSApellis Pharmaceuticals$41.03$34.89$16.10▼$41.14$5.25B-0.247.54 million shs68.61 million shsINSMInsmed$111.54-0.1%$108.77$90.39▼$212.75$24.19B0.784.60 million shs2.23 million shsLEGNLegend Biotech$28.04-6.3%$29.29$16.24▼$45.30$5.56B0.342.41 million shs1.52 million shsNKTRNektar Therapeutics$73.15+3.0%$68.79$21.02▼$109.00$2.40B1.131.18 million shs1.09 million shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLSApellis Pharmaceuticals0.00%0.00%0.00%+0.98%+128.13%INSMInsmed0.00%+7.95%+18.45%-31.87%+13.30%LEGNLegend Biotech0.00%+4.25%-8.31%+60.12%-15.39%NKTRNektar Therapeutics0.00%+11.61%+23.94%-4.93%+188.19%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPLSApellis Pharmaceuticals$41.03$34.89$16.10▼$41.14$5.25B-0.247.54 million shs68.61 million shsINSMInsmed$111.54-0.1%$108.77$90.39▼$212.75$24.19B0.784.60 million shs2.23 million shsLEGNLegend Biotech$28.04-6.3%$29.29$16.24▼$45.30$5.56B0.342.41 million shs1.52 million shsNKTRNektar Therapeutics$73.15+3.0%$68.79$21.02▼$109.00$2.40B1.131.18 million shs1.09 million shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPLSApellis Pharmaceuticals0.00%0.00%0.00%+0.98%+128.13%INSMInsmed0.00%+7.95%+18.45%-31.87%+13.30%LEGNLegend Biotech0.00%+4.25%-8.31%+60.12%-15.39%NKTRNektar Therapeutics0.00%+11.61%+23.94%-4.93%+188.19%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPLSApellis Pharmaceuticals 2.10Hold$36.29-11.54% DownsideINSMInsmed 2.96Moderate Buy$211.8689.94% UpsideLEGNLegend Biotech 2.67Moderate Buy$60.23114.80% UpsideNKTRNektar Therapeutics 2.73Moderate Buy$149.63104.55% UpsideCurrent Analyst Ratings BreakdownLatest INSM, LEGN, NKTR, and APLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026LEGNLegend Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/16/2026INSMInsmed MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$192.006/10/2026INSMInsmed Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/8/2026INSMInsmed Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/8/2026INSMInsmed JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$180.00 ➝ $179.006/5/2026INSMInsmed Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$205.00 ➝ $195.006/3/2026LEGNLegend Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/3/2026LEGNLegend Biotech UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$31.00 ➝ $49.006/3/2026LEGNLegend Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $65.006/2/2026NKTRNektar Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/1/2026LEGNLegend Biotech UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$31.00 ➝ $50.00(Data available from 7/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPLSApellis Pharmaceuticals$1.11B4.75$0.21 per share196.33$3.24 per share12.66INSMInsmed$606.42M39.87N/AN/A$3.46 per share32.24LEGNLegend Biotech$1.03B5.06N/AN/A$5.43 per share5.16NKTRNektar Therapeutics$55.23M44.75N/AN/A$4.41 per share16.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPLSApellis Pharmaceuticals$22.39M$1.0240.23N/AN/A12.06%39.71%13.20%7/30/2026 (Estimated)INSMInsmed-$1.28B-$5.75N/A137.70N/A-144.44%-130.11%-51.57%8/6/2026 (Estimated)LEGNLegend Biotech-$296.80M-$0.68N/A16.89N/A-21.98%-24.92%-14.87%8/10/2026 (Estimated)NKTRNektar Therapeutics-$164.08M-$8.42N/AN/AN/A-284.18%-85.40%-39.99%8/6/2026 (Estimated)Latest INSM, LEGN, NKTR, and APLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026LEGNLegend Biotech-$0.02-$0.03-$0.01-$0.30$306.51 million$305.10 million5/7/2026Q1 2026APLSApellis Pharmaceuticals-$0.2888$0.15+$0.4388$0.15$208.91 million$268.30 million5/7/2026Q1 2026INSMInsmed-$0.90-$0.76+$0.14-$0.76$300.81 million$305.96 million5/7/2026Q1 2026NKTRNektar Therapeutics-$1.5824-$1.82-$0.2377-$1.82$10.69 million$10.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/AINSMInsmedN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/ANKTRNektar TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPLSApellis Pharmaceuticals0.873.633.16INSMInsmed0.804.474.10LEGNLegend BiotechN/A2.132.05NKTRNektar TherapeuticsN/A10.2110.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPLSApellis Pharmaceuticals96.29%INSMInsmedN/ALEGNLegend Biotech70.89%NKTRNektar Therapeutics75.88%Insider OwnershipCompanyInsider OwnershipAPLSApellis Pharmaceuticals6.50%INSMInsmed2.10%LEGNLegend Biotech0.02%NKTRNektar Therapeutics2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPLSApellis Pharmaceuticals770128.02 million119.70 millionOptionableINSMInsmed1,664216.75 million212.20 millionOptionableLEGNLegend Biotech2,965185.74 million185.70 millionOptionableNKTRNektar Therapeutics22033.79 million32.94 millionOptionableINSM, LEGN, NKTR, and APLS HeadlinesRecent News About These CompaniesNektar Therapeutics (NASDAQ:NKTR) Insider Sells $397,670.00 in StockJuly 5 at 4:39 AM | americanbankingnews.comJonathan Zalevsky Sells 5,681 Shares of Nektar Therapeutics (NASDAQ:NKTR) StockJuly 3 at 6:21 AM | insidertrades.comNKTR Stock Clocks Best Day In Over 2 Months As Investors Await Upcoming Clinical Data In EczemaJuly 2, 2026 | finance.yahoo.comAnalyzing Nektar Therapeutics (NASDAQ:NKTR) and Qualigen Therapeutics (NASDAQ:QLGN)July 1, 2026 | americanbankingnews.comNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 26, 2026 | prnewswire.comWhat a $1.2 Million Insider Sale Means for Nektar With Shares Up 160% This Past YearJune 25, 2026 | finance.yahoo.com3 Biotech Takeover Targets Wall Street Is Watching After the Apogee DealJune 23, 2026 | 247wallst.comNektar Therapeutics (NASDAQ:NKTR) CEO Sells $603,200.00 in StockJune 19, 2026 | insidertrades.comNektar Therapeutics (NASDAQ:NKTR) Insider Sells $336,211.98 in StockJune 18, 2026 | insidertrades.comNektar Therapeutics $NKTR Stock Position Raised by BVF Inc. ILJune 18, 2026 | marketbeat.comArmistice Capital LLC Buys 328,000 Shares of Nektar Therapeutics $NKTRJune 18, 2026 | marketbeat.comACT Capital Management LLC Invests $2.17 Million in Nektar Therapeutics $NKTRJune 18, 2026 | marketbeat.comA Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price VolatilityJune 7, 2026 | finance.yahoo.comNektar Stockholders Approve Governance and Incentive Plan ChangesJune 5, 2026 | tipranks.comWhat Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare StockJune 5, 2026 | finance.yahoo.comNektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 3, 2026 | prnewswire.comNektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New YorkMay 27, 2026 | prnewswire.comWhy I'm Still Neutral On Nektar Therapeutics After Alopecia Areata Extension DataMay 26, 2026 | seekingalpha.comRussell 3000 Shuffle: Ocugen, Nektar slated to join among healthcare stocks; Nano-X to drop offMay 26, 2026 | msn.comNektar Therapeutics (NASDAQ:NKTR) Insider Sells $13,036.49 in StockMay 22, 2026 | insidertrades.comPatient Square Makes a Big Bet on Nektar Pharmaceuticals (NKTR) Purchasing 210,000 SharesMay 16, 2026 | fool.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINSM, LEGN, NKTR, and APLS Company DescriptionsApellis Pharmaceuticals NASDAQ:APLSApellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Insmed NASDAQ:INSM$111.54 -0.06 (-0.05%) Closing price 04:00 PM EasternExtended Trading$112.95 +1.41 (+1.26%) As of 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Legend Biotech NASDAQ:LEGN$28.04 -1.87 (-6.25%) Closing price 04:00 PM EasternExtended Trading$28.30 +0.26 (+0.92%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Nektar Therapeutics NASDAQ:NKTR$73.15 +2.11 (+2.97%) Closing price 04:00 PM EasternExtended Trading$73.64 +0.49 (+0.67%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Flash Crash or Cash? The AI Hardware Reset Investors Can’t Ignore KBR Insiders Are Buying While the Market Misreads Its Spinoff Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and Grains Contrarian Alert: 5 Downgraded Stocks That May Reward Long-Term Investors This Edge AI Stock Just Got a Huge Vote of Confidence From Wall Street AI Is Selling Off, But These 5 Stocks Could Benefit Next MarketBeat Week in Review – 06/29 - 07/03 Analysts Just Raised Price Targets On These 3 Semiconductor Equipment Stocks Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
